Johnson & Johnson (NYSE:JNJ) Shares Sold by Kingsview Wealth Management LLC

Kingsview Wealth Management LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJFree Report) by 5.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 104,401 shares of the company’s stock after selling 6,043 shares during the quarter. Johnson & Johnson comprises approximately 0.6% of Kingsview Wealth Management LLC’s portfolio, making the stock its 29th biggest position. Kingsview Wealth Management LLC’s holdings in Johnson & Johnson were worth $16,260,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Hibernia Wealth Partners LLC purchased a new stake in shares of Johnson & Johnson during the third quarter worth approximately $27,000. FNY Investment Advisers LLC purchased a new stake in shares of Johnson & Johnson during the third quarter worth approximately $37,000. Tower View Wealth Management LLC raised its stake in shares of Johnson & Johnson by 183.3% during the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 165 shares during the last quarter. Creative Capital Management Investments LLC grew its holdings in Johnson & Johnson by 43.0% during the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after acquiring an additional 86 shares during the period. Finally, VitalStone Financial LLC acquired a new position in Johnson & Johnson during the second quarter worth $48,000. Hedge funds and other institutional investors own 68.40% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of a number of recent analyst reports. TheStreet lowered Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, November 17th. Wells Fargo & Company lowered Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Morgan Stanley dropped their price objective on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 24th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, January 24th. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $176.14.

Read Our Latest Analysis on JNJ

Johnson & Johnson Stock Up 0.2 %

JNJ opened at $156.76 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37. The firm has a market cap of $377.37 billion, a P/E ratio of 11.35, a PEG ratio of 2.63 and a beta of 0.53. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97. The business’s fifty day simple moving average is $158.20 and its 200 day simple moving average is $158.83.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. The business had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. The business’s revenue for the quarter was down 9.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.35 earnings per share. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be given a dividend of $1.19 per share. The ex-dividend date of this dividend is Friday, February 16th. This represents a $4.76 annualized dividend and a yield of 3.04%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 34.47%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.